drugset / Trial / NCT02610348

Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

NCT02610348

Completed 122 enrolled Sanofi Pasteur, a Sanofi Company
Non-randomizedParallel-groupOpen-labelOther

Summary

Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6 months of age following Hep B vaccination at birth.

Timeline

Start
2015-11
Primary completion
2015-12
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject DTaP-HB-IPV Vaccine
Subject DTaP-IPV-HB-PRP~T Vaccine